ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2747

Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis

Yongjing CHENG Jr.1, Xiaolin Sun2, Yuling Chen Jr.3, Cibo Huang4, Haiteng Deng3 and Zhan-Guo Li5, 1Rheumatology and Immunology Department, Beijing Hospital, Ministry of Health, Beijing, China, 2People's hospital,Peking University, Beijing, China, 3Tsing hua University, Beijing, China, 4Beijing hospital, Beijing, China, 5Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: antibody microarray and biomarkers, Behcet's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Behcet’s disease (BD) is a chronic, multisystemic vasculitis, pathogenesis of BD remains enigmatic. Diagnosis of BD is sometimes difficult, and until now, no specific serological markers have been established. Identification of antigens incorporated into CICs provides information that may be helpful in developing diagnostic and treatment strategies for autoimmune diseases, and such information might be more relevant than information on free antigens.The purpose of this study is to seek candidate autoantigens in CIC in BD, analyze autoantiges through Orbitrap mass spectrometry, and detect antibody levels of candidate autoantigens through ELISA in different autoimmune diseases. 

Methods:

A novel proteomic strategy (immune complexome analysis) was developed, in which circulating immune complexes (CICs) were separated from pooling serum sample of 10 BD patients and 10 healthy controls, digested directly with trypsin, and then subjected to Orbitrap mass spectrometry for identifying and profiling antigens in CICs.  Anti-tubulin- a -1C antibody level were detected by Enzyme-linked immunosorbent assay (ELISA) in sera of 44 BD, 51 SLE, 51 SSc, 40 RA, 51 SS, 22 RAU, 13 TA, 25 AASV and 59 healthy volunteers.

Results:

 A totle of 22 antigens incorporated into CICs were found in CICs of BD patients, but not in RA and HC, including TAOK3, BAG3 and Tubulin-a-1C et al. The auto-antibody to one of the identified proteins, Tubulin-a-1C, was investigated by ELISA using a recombinant protein. The auto-antibody to Tubulin-a-1C were detected positive in 26 (59.0%) of the 44 patients with BD, 14 (27.5%) of the 51patients with SLE, 14 (27.5%) of the 51patients with SSc, 3 (7.5%) of the 40 patients with RA, 3(23.1%) of 13 TA, 1(4%) of 25 AASV and 2(3.39%)of 59 HC. The sensitivity and specificity of Tubulin-a-1C antibody in the diagnosis of BD were 59.0% and 82.7% respectively. Further analysis demonstrated that Tubulin-a-1C antobody was correlated with complications of deep venous thrombosis and erythema nodosum of BD(p<0.05), and meanwhile,levels of anti- Tubulin-a-1C antibody were correlated with levels of ESR , CRP and BVAS(p<0.05). 

Conclusion: Anti- Tubulin-a-1C antibody may be helpful in diagnosis and severity evaluation of BD, CIC relevant antigens may benefit understanding of the pathogenesis of venous thrombosis and erythema nodosum of BD.


Disclosure:

Y. CHENG Jr.,
None;

X. Sun,
None;

Y. Chen Jr.,
None;

C. Huang,
None;

H. Deng,
None;

Z. G. Li,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-potential-serum-biomarkers-for-behcet-disease-by-high-resolution-quantitative-proteomic-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology